Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome

Molecular Biology Reports

Volumn 39, Issue 2, 2012, Pages 937-943

  Kordi Tamandani, Dor Mohammad ^a   Hashemi, Mohammad ^b   Sharifi, Nooshin ^a   Kaykhaei, Mahmoud Ali ^c   Torkamanzehi, Adam ^a  

^a UNIVERSITY OF SISTAN AND BALUCHESTAN   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metabolic syndrome; Paraoxonase 1 (PON1); Polymorphism

Indexed keywords

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PARAOXONASE 1 GENE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; POLYMERASE CHAIN REACTION; RISK; RISK FACTOR;

ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN; PRIMER DNA;

ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IRAN; METABOLIC SYNDROME X; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84860317828     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0819-x     Document Type: Article

References (53)

1. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation 111:3465-3472 (Pubitemid 40923401)
2. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J (2003) Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation 108:414-419 (Pubitemid 36935533)
3. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607 (Pubitemid 19004941)
4. Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769-1778 (Pubitemid 40923091)
5. Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A (2007) Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 117:204-210 (Pubitemid 46454413)
6. Rutter MK, Meigs JB, Sullivan LM, D'Agostino R B Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation 110:380-385 (Pubitemid 38993845)
7. Lteif AA, Han K, Mather KJ (2005) Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112:32-38 (Pubitemid 40962566)
8. Pollex RL, Al-Shali KZ, House AA, Spence JD, Fenster A, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Hegele RA (2006) Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovasc Ultrason 4:28
9. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689 (Pubitemid 32893993)
10. Lee J, Heng D, Ma S, Chew S-K, Hughes K, Tai ES (2008) The metabolic syndrome and mortality: the Singapore cardiovascular cohort study. Clin Endocrinol Oxf 69:225-230 (Pubitemid 352009015)
11. Ma W-Y, Li H-Y, Hung CS, Lin M-S, Chiu F-C, Lin C-H, Shih S-R, Chuang L-M, Wei J-N (2009) Metabolic syndrome defined by IDF and AHA/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO. Diabetes Res Clin Pract 85:335-341
12. Wallenfeldt K, Hulthe J, Fagerberg B (2005) The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med 258:28-37 (Pubitemid 40904930)
13. Lu B, Yang Y, Song X, Dong X, Zhang Z, Zhou L, Li Y, Zhao N, Zhu X, Hu R (2006) An evaluation of the international diabetes federation definition of metabolic syndrome in Chinese patients older than 30 years and diagnosed with type 2 diabetes mellitus. Metabolism 55:1088-1096 (Pubitemid 44040985)
14. Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gabriel R, Williams K, Gomez-Gerique JA, Stern MP, Haffner SM (2003) Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 11:1480-1487 (Pubitemid 41127332)
15. Raymond SU, Leeder S, Greenberg HM (2006) Obesity and cardiovascular disease in developing countries: a growing problem and an economic threat. Curr Opin Clin Nutr Metab Care 9:111-116 (Pubitemid 44090033)
16. Prentice AM (2006) The emerging epidemic of obesity in developing countries. Int J Epidemiol 35:93-99 (Pubitemid 43205453)
17. Azizi F, Azadbakht L, Mirmiran P (2005) Trends in overweight, obesity and central fat accumulation among Tehranian adults between 1998-1999 and 2001-2002: Tehran lipid and glucose study. Ann Nutr Metab 49:3-8 (Pubitemid 41094827)
18. Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265:2037-2048 (Pubitemid 24325685)
19. Schork NJ (1997) Genetically complex cardiovascular traits. Origins, problems, and potential solutions. Hypertension 29:145-149 (Pubitemid 27074035)
20. Hegele RA (1997) The genetic basis of atherosclerosis. Int J Clin Lab Res 27:2-13
21. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507 (Pubitemid 26159866)
22. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-1684 (Pubitemid 41540360)
23. Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154
24. Zhang Y, Zheng F, Du H, Krepinsky JC, Segbo JAG, Zhou X (2006) Detecting the polymorphisms of paraoxonase (PON) cluster in Chinese Han population based on a rapid method. Clin Chim Acta 365:98-103 (Pubitemid 43196422)
25. Tomas M, Latorre G, Senti M, Marrugat J (2004) The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol 57:557-569 (Pubitemid 38997113)
26. Flekac M, Skrha J, Zidkova K, Lacinova Z, Hilgertova J (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 57:717-726
27. Costa LG, Vitalone A, Cole TB, Furlong CE (2005) Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550
28. Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516-521 (Pubitemid 30086111)
29. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480 (Pubitemid 32323376)
30. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST (2005) The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38:153-163 (Pubitemid 39656127)
31. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295-298 (Pubitemid 30336541)
32. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469-480
33. Hashemi M, Kordi-Tamandani DM, Sharifi N, Moazeni-Roodi A, Kaykhaei MA, Narouie B, Torkmanzehi A (2011) Paraoxonase and Arylesterase activities in metabolic syndrome in Zahedan, southeast Iran. Eur J Endocrinol 164(2):219-222
34. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516 (Pubitemid 19103235)
35. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, Ghavami S (2010) Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 9:333-339
36. Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Ta-heri M, Bardestani GR, Zakeri Z, Kordi-Tamandani DM, Ghav-ami S (2010) The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 9:1735-1741
37. Gupta N, Gill K, Singh S (2009) Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 130:361-368
38. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76 (Pubitemid 23063292)
39. Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123-134 (Pubitemid 32216123)
40. Ergen A, Kilicoglu O, Ozger H, Agachan B, Isbir T (2010) Paraoxonase 1 192 and 55 polymorphisms in osteosarcoma. Mol Biol Rep. doi:10.1007/s11033-010- 0538-8
41. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Tavilani H, Pour-motabbed T, Shakiba E, Kiani A, Aminian M, Alibakhshi R, Bartels C (2011) Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep. doi:10.1007/s11033-011-0696-3
42. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipo-protein oxidation with a peroxynitrite donor. J Biol Chem 276:24473-24481
43. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-442 (Pubitemid 30145555)
44. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-264
45. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Bio-chem 35:197-203 (Pubitemid 34634181)
46. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via inter-leukin-6. J Biol Chem 276:1923-1929 (Pubitemid 32109669)
47. Pola R, Gaetani E, Flex A, Gerardino L, Aloi F, Flore R, Serric-chio M, Pola P, Bernabei R (2003) Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population. Dement Geriatr Cogn Disord 15:88-91 (Pubitemid 36098761)
48. Scacchi R, Gambina G, Martini MC, Broggio E, Vilardo T, Corbo RM (2003) Different pattern of association of paraoxonase Gln192-[Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett 339: 17-20 (Pubitemid 36263211)
49. Sodeyama N, Yamada M, Itoh Y, Suematsu N, Matsushita M, Otomo E, Mizusawa H (1999) No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology 53:1146-1148 (Pubitemid 29442144)
50. Helbecque N, Cottel D, Codron V, Berr C, Amouyel P (2004) Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett 358:41-44 (Pubitemid 38315207)
51. Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, Reddy KS, Prabhakaran D (2010) Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocar-dial infarction and association with oxidized low density lipo-protein. Indian J Med Res 131:522-529
52. Ozturk O, Kagnici OF, Ozturk T, Durak H, Tuzuner BM, Ki-sakesen HI, Cakalir C, Isbir T (2009) 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res 29:4041-4046
53. Paragh G, Seres I, Harangi M, Pocsai Z, Asztalos L, Locsey L, Szeles G, Kardos L, Varga E, Karpati I, Adany R (2009) Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease. Nephron Clin Pract 113: c46-c53